GeneCentric Data Suggest Fragmentomics Could Expand Liquid Biopsy Beyond Mutation Testing
Presentations at AACR 2026 will showcase fragmentomics-based technology for detecting therapeutic markers and providing prognostic insight.
Presentations at AACR 2026 will showcase fragmentomics-based technology for detecting therapeutic markers and providing prognostic insight.
The Elecsys NfL test measures a protein associated with nerve cell injury to monitor disease activity in patients with relapsing remitting multiple sclerosis.
A peer-reviewed economic analysis challenges the assumption that erythrocyte sedimentation rate and C-reactive protein tests are interchangeable, finding that combined testing reduces misdiagnoses and lowers overall costs.
The accreditation covers liver health diagnostics, including Hepatotrack, a molecular diagnostic liquid biopsy that is predictive of acute liver rejection post-liver transplant.
The owner of an Oregon clinical laboratory allegedly submitted tens of millions in fraudulent claims to Medicare Advantage plans for laboratory testing services that were never ordered or performed.
Lot-to-lot reagent inconsistencies can have significant effects on patient test results.
The blood-based genomic profiling assay for advanced solid tumors is now reimbursable under Medicare’s policy covering plasma-based genomic profiling tests.
This clinical lab conference spotlight looks at why ADLM 2026 belongs on the radar for CLP readers. From the scientific program to the Clinical Lab Expo, the event offers practical ideas, fresh technology, and real conversations for people working across diagnostics and laboratory medicine. For lab professionals who want useful insight, sharper perspective, and stronger industry connections, this is a smart place to be.